FDA accepts Flexion’s NDA for osteoarthritis steroid injection

Flexion Therapeutics (NSDQ:FLXN) said today that the FDA accepted its New Drug Application for Zilretta – its extended-release steroid injection. The Burlington, Mass.-based company won Fast Track status from the watchdog for its osteoarthritis injection in 2015.

Flexion touts Zilretta as the 1st intra-articular, extended-release therapy for patients with knee osteoarthritis pain. The injection uses microsophere technology to combine a commonly administered, short-acting corticosteroid with a polylactic-co-glycolic acid matrix.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA accepts Flexion’s NDA for osteoarthritis steroid injection appeared first on MassDevice.

from MassDevice http://ift.tt/2kF0JXw